Zura Bio expands HS trial to 225 patients; expects Q4 2026 data; cash through 2027

Zura Bio Ltd

Phase 2 TibuSHIELD trial in HS expanded from 180 to 225 participants; topline data expected Q4 2026.
Phase 2 TibuSURE trial in SSc: topline data anticipated in first half of 2027.
Cash and equivalents sufficient to fund operations through 2027, beyond both data readouts.
Tibulizumab is a first-in-class bispecific antibody targeting IL-17 and BAFF pathways.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.